Real-Time Detection of ESR1 Mutation in Blood by Droplet Digital PCR in the PADA-1 Trial: Feasibility and Cross-Validation with NGS - Université Paris Cité Accéder directement au contenu
Article Dans Une Revue Analytical Chemistry Année : 2022

Real-Time Detection of ESR1 Mutation in Blood by Droplet Digital PCR in the PADA-1 Trial: Feasibility and Cross-Validation with NGS

Celine Callens
  • Fonction : Auteur correspondant
  • PersonId : 1134859

Connectez-vous pour contacter l'auteur
Jean Luc Canon
  • Fonction : Auteur
Sandrine Marques
Anne Vincent-Salomon
Emmanuelle Jeannot
Ivan Bieche
  • Fonction : Auteur

Résumé

The clinical actionability of circulating tumor DNA requires sensitive detection methods with a short turnaround time. In the PADA-1 phase 3 trial (NCT03079011), metastatic breast cancer patients treated with an aromatase inhibitor and palbociclib were screened every 2 months for activating ESR1 mutations in blood (bESR1mut). We report the feasibility of the droplet digital polymerase chain reaction (ddPCR) and cross-validation with next-generation sequencing (NGS). bESR1mut testing was centralized in two platforms using the same ddPCR assay. Results were reported as copies/mL of plasma and mutant allele frequency (MAF). We analyzed 200 positive ddPCR samples with an NGS assay (0.5-1% sensitivity). Overall, 12,552 blood samples were collected from 1017 patients from 83 centers. Among the 12,525 available samples with ddPCR results, 11,533 (92%) were bESR1mut-negative. A total of 267 patients newly displayed bESR1mut (26% patients/2% samples) with a median copy number of 14/mL (range: 4-1225) and a median MAF of 0.83% (0.11-35), 648 samples (20% patients/5% samples) displayed persistent bESR1mut, and 77 (<1%) samples encountered a technical failure. The median turnaround time from blood drawing to result notification was 13 days (Q1:9; Q3:21 days). Among 200 ddPCR-positive samples tested, NGS detected bESR1mut in 168 (84%); 25 of the 32 cases missed by NGS had low MAF and/or low coverage. In these 200 samples, bESR1mut MAF by both techniques had an excellent intraclass correlation coefficient (ICC = 0.93; 95% CI [0.85; 0.97]). These results from a large-scale trial support the feasibility and accuracy of real-time bESR1mut tracking by ddPCR, opening new opportunities for therapeutic interventions.
Fichier non déposé

Dates et versions

hal-03673620 , version 1 (20-05-2022)

Identifiants

Citer

Celine Callens, François Clément Bidard, Anaïs Curto-Taribo, Olfa Trabelsi-Grati, Samia Melaabi, et al.. Real-Time Detection of ESR1 Mutation in Blood by Droplet Digital PCR in the PADA-1 Trial: Feasibility and Cross-Validation with NGS. Analytical Chemistry, 2022, 94 (16), pp.6297-6303. ⟨10.1021/acs.analchem.2c00446⟩. ⟨hal-03673620⟩
84 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More